MAPT and Alzheimer disease: Studies with AD mouse models have generally been performed using transgenic mice to induce Aβ accumulation and deposition by overexpressing a mutant amyloid precursor protein (APP) transgene, or with a combination of mutant APP and PSEN1 or MAPT transgenes.